IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

LICITRA, LISA FRANCESCA LINDA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 24.396
NA - Nord America 20.657
AS - Asia 18.908
SA - Sud America 2.061
AF - Africa 372
OC - Oceania 216
Continente sconosciuto - Info sul continente non disponibili 34
Totale 66.644
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 19.745
DE - Germania 10.110
CN - Cina 5.915
SG - Singapore 4.952
GB - Regno Unito 3.808
IT - Italia 3.598
HK - Hong Kong 1.845
BD - Bangladesh 1.538
BR - Brasile 1.477
RU - Federazione Russa 1.422
VN - Vietnam 1.364
FR - Francia 1.111
SE - Svezia 894
IN - India 830
JP - Giappone 694
IE - Irlanda 591
CA - Canada 570
ES - Italia 530
NL - Olanda 437
FI - Finlandia 429
ID - Indonesia 321
KR - Corea 273
TW - Taiwan 236
MX - Messico 209
AU - Australia 202
AR - Argentina 187
TR - Turchia 168
BE - Belgio 164
CH - Svizzera 157
PL - Polonia 151
AT - Austria 145
DK - Danimarca 138
GR - Grecia 127
CO - Colombia 123
EC - Ecuador 99
PT - Portogallo 99
UA - Ucraina 99
IQ - Iraq 87
CI - Costa d'Avorio 86
PH - Filippine 79
TH - Thailandia 79
MY - Malesia 75
HU - Ungheria 74
IL - Israele 74
MA - Marocco 73
ZA - Sudafrica 66
RO - Romania 53
IR - Iran 50
PK - Pakistan 50
CL - Cile 49
SA - Arabia Saudita 46
UZ - Uzbekistan 43
VE - Venezuela 42
CZ - Repubblica Ceca 40
NO - Norvegia 39
EG - Egitto 36
PE - Perù 36
TN - Tunisia 28
JO - Giordania 26
AE - Emirati Arabi Uniti 24
SK - Slovacchia (Repubblica Slovacca) 24
HR - Croazia 23
KE - Kenya 23
CR - Costa Rica 21
RS - Serbia 21
JM - Giamaica 20
SI - Slovenia 18
EU - Europa 17
NP - Nepal 17
PY - Paraguay 17
LT - Lituania 16
UY - Uruguay 16
DO - Repubblica Dominicana 14
GT - Guatemala 13
NZ - Nuova Zelanda 13
AZ - Azerbaigian 12
BG - Bulgaria 12
BO - Bolivia 12
EE - Estonia 12
HN - Honduras 12
CY - Cipro 11
KZ - Kazakistan 11
LU - Lussemburgo 11
OM - Oman 11
DZ - Algeria 10
MD - Moldavia 10
PA - Panama 10
SC - Seychelles 10
SY - Repubblica araba siriana 10
NI - Nicaragua 9
LB - Libano 8
LV - Lettonia 8
NG - Nigeria 8
TT - Trinidad e Tobago 8
AL - Albania 7
AM - Armenia 7
AP - ???statistics.table.value.countryCode.AP??? 7
KW - Kuwait 7
GE - Georgia 6
KG - Kirghizistan 6
Totale 66.521
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 8.843
Southend 3.096
Singapore 2.636
Ashburn 1.818
Dallas 1.618
Hong Kong 1.583
San Jose 1.237
Milan 978
Fairfield 881
Chandler 824
Beijing 757
Santa Clara 688
Seattle 679
Council Bluffs 677
Princeton 657
Wilmington 614
Dublin 582
New York 512
Los Angeles 489
Houston 429
Woodbridge 428
Guangzhou 397
Lauterbourg 373
Ho Chi Minh City 371
Redwood City 364
Nanjing 323
Hanoi 310
Cambridge 298
Buffalo 291
Shanghai 287
Tokyo 285
Helsinki 283
Ann Arbor 266
Rome 257
Moscow 250
Bengaluru 249
Des Moines 249
Jakarta 207
Munich 198
Hefei 194
Seoul 191
São Paulo 182
Jinan 166
Chicago 163
Tianjin 160
Boardman 153
Dearborn 149
Shenyang 133
London 131
Hangzhou 121
Berlin 118
Naples 116
Toronto 111
Columbus 110
Taipei 110
Shenzhen 109
Changsha 107
Duncan 107
Cangzhou 106
Grafing 99
San Diego 99
Madrid 98
The Dalles 98
Nuremberg 97
Amsterdam 93
Phoenix 90
Nanchang 87
Wuhan 87
Abidjan 85
Atlanta 83
Dong Ket 77
Florence 73
Washington 71
Hebei 67
Athens 66
Istanbul 66
Montreal 65
Paris 65
Ottawa 63
Zhengzhou 62
Chengdu 61
Rio de Janeiro 61
Da Nang 58
Philadelphia 58
Denver 57
Vienna 57
Barcelona 56
Bologna 56
Jiaxing 56
Turin 56
Mumbai 50
San Francisco 50
Brussels 48
Boston 47
Hyderabad 47
Warsaw 46
Fuzhou 45
Bogotá 44
Buenos Aires 44
Central District 44
Totale 40.753
Salva come PNG Salva come JPEG
Nome #
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial 4.614
Lenvatinib-induced renal failure : two first-time case reports and review of literature 1.154
Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up† 936
Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up 718
Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040) 615
Nivolumab for recurrent squamous-cell carcinoma of the head and neck 552
Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations 525
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study 512
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer 486
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial 462
Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer 459
A functional gene expression analysis in epithelial sinonasal cancer : Biology and clinical relevance behind three histological subtypes 450
Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer 445
Adenocarcinoma of ethmoid sinus : an occupational disease = Adenocarcinoma dei seni paranasali : una malattia professionale 436
Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial 417
Ferroptosis-Related Gene Signatures: Prognostic Role in HPV-Positive Oropharyngeal Squamous Cell Carcinoma 412
Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach 395
TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: A randomized phase II EORTC trial 379
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016 370
Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities? 347
Benefits and Risks of Machine Learning Decision Support System 339
Italian version of the M.D. Anderson Symptom Inventory - €”Head and Neck Module : linguistic validation 337
A multicenter randomized trial for quality of life evaluation by non-invasive intelligent tools during post-curative treatment follow-up for head and neck cancer: Clinical study protocol 332
Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck : efficacy and safety in CheckMate 141 by age 332
Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic : an international consensus 316
Role of IMRT/VMAT-Based Dose and Volume Parameters in Predicting 5-Year Local Control and Survival in Nasopharyngeal Cancer Patients 314
Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients 302
Interplay between MRI radiomics and immune gene expression signatures in oral squamous cell carcinoma 299
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) 295
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141) : health-related quality-of-life results from a randomised, phase 3 trial 293
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study 290
Nivolumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use 288
PATIENT VOICES, a project for the integration of the systematic assessment of patient reported outcomes and experiences within a comprehensive cancer center: a protocol for a mixed method feasibility study 285
Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma 280
Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC) 276
Tailoring treatment of salivary duct carcinoma (SDC) by liquid biopsy:ARv7 expression in circulating tumor cells 274
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial 270
Modelling radiation‐induced salivary dysfunction during IMRT and chemotherapy for nasopharyngeal cancer patients 265
Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project 261
TP53, P14ARF, P16INK4a and H-ras gene molecular analysis in intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses 259
Radiotherapy for unresectable sinonasal cancers : dosimetric comparison of intensity modulated radiation therapy with coplanar and non-coplanar volumetric modulated arc therapy 256
Gene Expression Clustering and Selected Head and Neck Cancer Gene Signatures Highlight Risk Probability Differences in Oral Premalignant Lesions 256
Big Data in Head and Neck Cancer 252
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19805 patients, on behalf of MACH-NC group 252
Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract 248
Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies : literature review and consensus 244
Do not throw the baby out with the bathwater : SELECT a personalized, de-escalated lenvatinib schedule allows response in locally advanced DTC while controlling major drug-related bleeding 244
Role of pretreatment 18F-FDG PET/CT parameters in predicting outcome of non-endemic EBV DNA-related nasopharyngeal cancer (NPC) patients treated with IMRT and chemotherapy 244
Critical analysis of locoregional failures following intensity-modulated radiotherapy for nasopharyngeal carcinoma 242
Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers : a European consensus position paper 241
Multivariable model for predicting acute oral mucositis during combined IMRT and chemotherapy for locally advanced nasopharyngeal cancer patients 239
PD-L1 Expression in Unresectable Locally Advanced or Metastatic Skin Squamous Cell Carcinoma Treated with Anti-Epidermal Growth Factor Receptor Agents 239
Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer : An Italian validation study 238
The Interplay between Age and Viral Status in EBV-Related Nasopharyngeal and HPV-Related Oropharyngeal Carcinoma Patients 236
Evidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neck 235
Baseline mri-radiomics can predict overall survival in non-endemic ebv-related nasopharyngeal carcinoma patients 235
Treatment-related mortality in head and neck cancer patients receiving chemotherapy and radiation: results of a meta-analysis of published trials 231
Complete Response to Nivolumab in Recurrent/Metastatic HPV-Positive Head and Neck Squamous Cell Carcinoma Patient After Progressive Multifocal Leukoencephalopathy: A Case Report 231
Tumor Biomarkers for the Prediction of Distant Metastasis in Head and Neck Squamous Cell Carcinoma 227
A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas : Translational analyses and clinical impact 225
The day after De-ESCALaTE and RTOG 1016 trials results 224
Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma 223
Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer 222
Are Fusion Transcripts in Relapsed/ Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies? 221
Response of the Istituto Nazionale Tumori of Milan Head & Neck Cancer Unit to the COVID-19 outbreak 220
Health care-associated infections in patients with head and neck cancer treated with chemotherapy and/or radiotherapy 218
Transcriptomics and Epigenomics in head and neck cancer: available repositories and molecular signatures 218
Hope in cancer patients : The relational domain as a crucial factor 217
T-cell therapy for EBV-associated nasopharyngeal carcinoma : preparative lymphodepleting chemotherapy does not improve clinical results 216
Locally advanced epithelial sinonasal tumors: The impact of multimodal approach 216
Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma 215
Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/ metastatic head and neck squamous cell carcinoma treated with nivolumab 214
HER2 status in recurrent/metastatic androgen receptor overexpressing salivary gland carcinoma patients 214
Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma : a phase II trial of 22 patients 213
Motesanib diphosphate in progressive differentiated thyroid cancer 213
Comment on 'Impact of intra-arterial chemotherapy including internal carotid artery for advanced paranasal sinus cancers involving the skull base' 212
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis : a randomized, double-blind study 211
The observational clinical registry (cohort design) of the European Reference Network on Rare Adult Solid Cancers: The protocol for the rare head and neck cancers 209
Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a nonendemic area 207
Identification of potentially druggable molecular alterations in skin adnexal malignancies 207
An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer 205
Pain management in head and neck cancer patients undergoing chemo-radiotherapy : Clinical practical recommendations 205
Prognostic role of primary tumor, nodal neck, and retropharyngeal GTVs for unresectable sinonasal cancers treated with IMRT and chemotherapy 203
Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma 203
Rationale and design of LUX-Head & Neck 1 : a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy 202
Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment 202
Integrative miRNA-Gene expression analysis enables refinement of associated biology and prediction of response to cetuximab in head and neck squamous cell cancer 202
Head and neck cancer 201
Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy 201
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study 198
Prevalence of Fatigue in Head and Neck Cancer Survivors 198
An old but still unanswered question in recurrent or metastatic salivary duct carcinoma 198
Perspectives in immunotherapy: Meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016 197
Pan-Asian adaptation of the EHNS–ESMO–ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck 197
Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer 196
Lung metastasectomy in adenoid cystic cancer : is it worth it? 196
Tumor molecular landscape of Epstein-Barr virus (EBV) related nasopharyngeal carcinoma in EBV-endemic and non-endemic areas: Implications for improving treatment modalities 195
Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer 193
Activity and safety of afatinib in a window pre-operative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN) 193
Quality of life in head and neck cancer survivors: the Big Data for Quality of Life study 192
Totale 33.693
Salva come PNG Salva come JPEG
Categoria #
all - tutte 164.495
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 164.495
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20225.336 527 414 392 406 466 364 396 391 469 435 237 839
2022/20234.738 576 359 541 413 429 826 199 246 474 191 272 212
2023/20249.379 200 313 247 268 654 298 1.352 1.202 712 1.228 1.430 1.475
2024/202510.955 1.272 1.711 1.101 1.125 529 412 378 885 553 681 738 1.570
2025/202623.725 1.553 1.037 2.773 1.298 1.915 1.585 2.595 1.493 2.793 1.569 2.456 2.658
2026/2027641 641 0 0 0 0 0 0 0 0 0 0 0
Totale 69.680